Showing 1341-1350 of 8179 results for "".
Integrated Search Marketing: The New Search Paradigm
https://practicaldermatology.com/topics/practice-management/integrated-search-marketing-the-new-search-paradigm/21510/One can say with a fair amount of certainty that the time of the Integrated Search Marketing (ISM) has arrived.How to Integrate Physician-Dispensed Products
https://practicaldermatology.com/topics/general-topics/PD0609_10-php/22819/With the correct protocols, staff training, and product selection, physician dispensing can help retain your current patient base and assist in marketing to new patients.Upadacitinib and Cardiovascular Events in AD
https://practicaldermatology.com/issues/october-2025/upadacitinib-and-cardiovascular-events-in-ad/39755/A recent review examined whether upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor approved for atopic dermatitis (AD) and other chronic inflammatory diseases, may—despite a boxed warning to the contrary—confer cardioprotective and thromboprotective effects.Cosmetic Options in Female Hair Loss
https://practicaldermatology.com/issues/august-2025/female-hair/36697/Female hair loss is a common issue addressed by dermatologists. It is a time-consuming problem to assess and treat. This article provides a methodical approach to female hair loss, including cosmetic options.Solving the Keloid Conundrum
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/solving-the-keloid-conundrum/20488/Are cosmetic treatments too risky for patients prone to keloids?Dealing With Unhappy Cosmetic Patients
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dealing-with-unhappy-cosmetic-patients/23870/Tips on avoiding and appeasing difficult patients.GLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muVitiligo: Understanding Your Options
https://practicaldermatology.com/youngmd-connect/wrap-ups/vitiligo-understanding-your-options/29890/Showing up is half the battle, it has often been said. According to dermatologist Nanette Silverberg, MD, FAAP, FAAD, chief of pediatric dermatology at Mount Sinai Health System in New York, that adage applied to the attendees at a recent YoungMD Connect virtual session featuring two expert presentaIn The Pipeline: Phase 1, 2, and 3
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/pipeline-phase-1-2-and-3/29087/This summary provides the latest news on of some of the recent Phase 1, Phase 2, and Phase 3 clinical studies for psoriasis treatments.Rosacea Unveiled: A YoungMD Connect Open Discussion with Dr. Corey Hartman
https://practicaldermatology.com/youngmd-connect/wrap-ups/rosacea-unveiled-a-youngmd-connect-open-discussion-with-dr-corey-hartman/27168/In his YoungMD Connect virtual session on the topic of rosacea, Dr. Corey Hartman shared extensive experience with the eager viewing audience. Topics discussed included treating patients with rosacea, including those with skin of color, as well as clinical pearls on diagnosing and managing this comm